- Home
- ICCC vs DYAI Comparison
ICCC vs DYAI Comparison
Compare ICCC & DYAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICCC
- DYAI
- Stock Information
- Founded
- ICCC 1982
- DYAI 1979
- Country
- ICCC United States
- DYAI United States
- Employees
- ICCC N/A
- DYAI N/A
- Industry
- ICCC Biotechnology: Pharmaceutical Preparations
- DYAI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ICCC Health Care
- DYAI Health Care
- Exchange
- ICCC Nasdaq
- DYAI Nasdaq
- Market Cap
- ICCC 48.3M
- DYAI 54.4M
- IPO Year
- ICCC 1987
- DYAI 2004
- Fundamental
- Price
- ICCC $5.50
- DYAI $1.23
- Analyst Decision
- ICCC
- DYAI Strong Buy
- Analyst Count
- ICCC 0
- DYAI 1
- Target Price
- ICCC N/A
- DYAI $6.00
- AVG Volume (30 Days)
- ICCC 39.3K
- DYAI 31.1K
- Earning Date
- ICCC 05-14-2025
- DYAI 05-13-2025
- Dividend Yield
- ICCC N/A
- DYAI N/A
- EPS Growth
- ICCC N/A
- DYAI N/A
- EPS
- ICCC N/A
- DYAI N/A
- Revenue
- ICCC $26,493,169.00
- DYAI $3,495,389.00
- Revenue This Year
- ICCC N/A
- DYAI $117.40
- Revenue Next Year
- ICCC N/A
- DYAI N/A
- P/E Ratio
- ICCC N/A
- DYAI N/A
- Revenue Growth
- ICCC 51.63
- DYAI 20.58
- 52 Week Low
- ICCC $3.34
- DYAI $0.93
- 52 Week High
- ICCC $5.82
- DYAI $2.67
- Technical
- Relative Strength Index (RSI)
- ICCC 59.13
- DYAI 40.54
- Support Level
- ICCC $4.63
- DYAI $1.20
- Resistance Level
- ICCC $5.72
- DYAI $1.28
- Average True Range (ATR)
- ICCC 0.42
- DYAI 0.07
- MACD
- ICCC 0.05
- DYAI -0.00
- Stochastic Oscillator
- ICCC 79.82
- DYAI 25.93
About ICCC ImmuCell Corporation
ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.
About DYAI Dyadic International Inc.
Dyadic International Inc is a world-wide biotechnology platform company. The company has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins, and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.